FDA’s New Metabolic Diseases Committee Tentatively Approves Drug for Ultra-Rare Disease | Exclusive Article from FDA Today
In the initial meeting of the FDA’s Genetic Metabolic Diseases Advisory Committee, discussions focused on a drug called arimoclomol, developed by Zevra, intended to treat the ultra-rare lysosomal storage disorder known as Niemann-Pick Type C. This session marked Zevra’s second attempt to gain approval for the drug after previous efforts had fallen short. The committee […]